HIGH-DOSE GADOTERIDOL IN MR IMAGING OF INTRACRANIAL NEOPLASMS

被引：84

作者：

RUNGE, VM

KIRSCH, JE

BURKE, VJ

PRICE, AC

NELSON, KL

THOMAS, GS

DEAN, BL

LEE, C

机构：

[1] Magnetic Resonance Imaging and Spectroscopy Center, University of Kentucky Medical Center, Lexington, Kentucky, 40536-0084, Rm HM103

[2] Albany Medical Center, Albany, New York

[3] Clarkson Memorial Hospital, Omaha

来源：

JMRI-JOURNAL OF MAGNETIC RESONANCE IMAGING | 1992年 / 2卷 / 01期

关键词：

BRAIN; MR; BRAIN NEOPLASMS; SECONDARY; CONTRAST ENHANCEMENT; GADOLINIUM;

D O I：

10.1002/jmri.1880020103

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Twelve patients with a high suspicion of brain metastases by previous clinical or radiologic examinations were studied in a phase III investigation with magnetic resonance (MR) imaging at 1.5 T after a bolus intravenous injection of 0.1 mmol/kg gadoteridol followed at 30 minutes by a second bolus injection of 0.2 mmol/kg gadoteridol. All lesions were best demonstrated (showed greatest enhancement) at the 0.3-mmol/kg (cumulative) dose, with image analysis confirming signal intensity enhancement in the majority of cases after the second gadoteridol injection. More lesions were detected with the 0.3-mmol/kg dose than with the 0.1-mmol/kg dose, and more lesions were detected with the 0.1-mmol/kg dose than on precontrast images. In this limited clinical trial, high-dose gadoteridol injection (0.3-mmol/kg cumulative dose) provided improved lesion detection on MR images specifically in intracranial metastatic disease.

引用

页码：9 / 18

页数：10

共 13 条

[1]

Runge VM, Gelblum DY, Pacetti ML, Et al., Gd‐HP‐DO3A in clinical MR imaging of the brain, Radiology, 177, pp. 393-400, (1990)

[2]

Runge VM, Dean B, Lee C, Et al., Phase III clinical evaluation of Gd‐HP‐DO3A in head and spine disease, JMRI, 1, pp. 47-56, (1991)

[3]

Niendorf HP, Laniado M, Semmler W, Et al., Dose administration of gadolinium DTPA in MR imaging of intracranial tumors, AJNR, 8, pp. 803-815, (1987)

[4]

Tweedle MF, Nonionic or neutral? (letter), Radiology, 178, (1991)

[5]

Weinmann HJ, Press WR, Gries H, (1989)

[6]

Carollo BR, Runge VM, Price AC, Et al., The prospective evaluation of Gd‐DTPA in 225 consecutive cranial cases: adverse reactions and diagnostic value, Magn Reson Imaging, 8, pp. 381-393, (1990)

[7]

Davis PC, Hudgins PA, Peterman SB, Hoffman JC, Diagnosis of cerebral metastases: double‐dose delayed CT vs contrast enhanced MR imaging, AJNR, 12, pp. 293-300, (1991)

[8]

Runge VM, Clanton JA, Lukehart CM, Et al., Paramagnetic agents for contrast‐enhanced NMR imaging: a review, AJR, 141, pp. 1209-1215, (1983)

[9]

Yuh WT, Fisher DJ, Engelken JD, Et al., MR evaluation of CNS tumors: dose comparison study with gadopentetate dimeglumine and gadioteridol, Radiology, 180, pp. 485-491, (1991)

[10]

Russell EJ, Geremia GK, Johnson CE, Et al., Multiple cerebral metastases: detectability with Gd‐DTPA‐enhanced MR imaging, Radiology, 165, pp. 609-617, (1987)

← 1 2 →